Live Stock Coverage: CorMedix Inc. Just Recorded A Sigfniciant Increase

Live Stock Coverage: CorMedix Inc. Just Recorded A Sigfniciant Increase

The stock of CorMedix Inc. (NYSEMKT:CRMD) is a huge mover today! About 526,430 shares traded hands. CorMedix Inc. (NYSEMKT:CRMD) has risen 59.66% since March 2, 2016 and is uptrending. It has outperformed by 51.40% the S&P500.
The move comes after 5 months positive chart setup for the $136.86 million company. It was reported on Oct, 5 by Barchart.com. We have $8.24 PT which if reached, will make NYSEMKT:CRMD worth $213.50M more.

Analysts await CorMedix Inc. (NYSEMKT:CRMD) to report earnings on November, 10. They expect $-0.15 earnings per share, down 7.14% or $0.01 from last year’s $-0.14 per share. After $-0.13 actual earnings per share reported by CorMedix Inc. for the previous quarter, Wall Street now forecasts 15.38% negative EPS growth.

According to Zacks Investment Research, “CorMedix Inc. is a development-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix’s goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications. The Company’s therapeutic candidates for cardiorenal disease may be small molecules, biologicals, devices and/or diagnostics (tests) that enable therapy. Its product pipeline includes: CRMD001, a unique formulation Deferiprone which is in development to prevent Contrast-Induced Acute Kidney Injury and to slow progression of Chronic Kidney Disease; CRMD002, a diagnostic test for urinary labile iron; CRMD003 (Neutrolin®, an antimicrobial/anticoagulant solution) is in development to prevent Catheter Related Bloodstream Infection; CRMD004, a pressure sensitive gel which has many uses, including extending the benefits of Neutrolin®. CorMedix Inc. is based in Summit, New Jersey.”

Insitutional Activity: The institutional sentiment decreased to 0.54 in Q2 2016. Its down 1.10, from 1.64 in 2016Q1. The ratio worsened, as 18 funds sold all CorMedix Inc. shares owned while 17 reduced positions. 10 funds bought stakes while 9 increased positions. They now own 4.22 million shares or 33.14% less from 6.32 million shares in 2016Q1.
State Street accumulated 17,767 shares or 0% of the stock. Bnp Paribas Arbitrage owns 23 shares or 0% of their US portfolio. Fincl Bank Of America De has 0% invested in the company for 11,861 shares. Kanaly Communication last reported 2,570 shares in the company. Wells Fargo Communications Mn holds 3,312 shares or 0% of its portfolio. Geode Management Limited Liability holds 0% or 182,021 shares in its portfolio. Susquehanna Llp has 45,329 shares for 0% of their US portfolio. Blackrock Inv Mngmt Ltd Liability Corporation holds 0% of its portfolio in CorMedix Inc. (NYSEMKT:CRMD) for 5,891 shares. Moreover, Commonwealth Equity has 0% invested in CorMedix Inc. (NYSEMKT:CRMD) for 10,091 shares. Blackrock Advisors Ltd last reported 7,588 shares in the company. The United Kingdom-based Lmr Partners Ltd Liability Partnership has invested 0.01% in CorMedix Inc. (NYSEMKT:CRMD). Blackrock Institutional Trust Com Na last reported 494,922 shares in the company. Ray Gerald L & Associate has invested 0.04% of its portfolio in CorMedix Inc. (NYSEMKT:CRMD). Private Advisor Ltd holds 0.01% of its portfolio in CorMedix Inc. (NYSEMKT:CRMD) for 108,333 shares. Barclays Public Limited holds 0% or 3,654 shares in its portfolio.

Insider Transactions: Since May 18, 2016, the stock had 4 buys, and 9 selling transactions for $406,065 net activity. Shares for $34,496 were bought by Kaplan Myron on Friday, August 19. Pfaffle Antony had sold 12,700 shares worth $34,656. Another trade for 50,000 shares valued at $144,178 was sold by Lefkowitz Steven W. $24,940 worth of CorMedix Inc. (NYSEMKT:CRMD) was bought by TELLEZ CORA M. 18,600 shares with value of $30,690 were bought by Markvicka Taunia on Thursday, August 25. Duffy Matthew sold $126,008 worth of stock or 46,106 shares.

More news for CorMedix Inc. (NYSEMKT:CRMD) were recently published by: Finance.Yahoo.com, which released: “CorMedix, Inc. Announces Signing of an Agreement with POETIC (Pediatric …” on September 15, 2016. Valuewalk.com‘s article titled: “Resonant Down 70%… Could CorMedix Inc. (CRMD) Be Next?” and published on April 13, 2015 is yet another important article.

CRMD Company Profile

CorMedix Inc., incorporated on July 28, 2006, is a commercial pharmaceutical and medical device company. The Firm in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Firm has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment